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Tranilast (N-[3,4-dimethoxycinnamoyl]anthranilic acid) is a
synthetic compound that we have recently reported to
inhibit transforming growth factor-b1 (TGF-b1)-induced
tubulointerstitial fibrosis in the kidney. Connective tissue
growth factor (CTGF) is recognized as a potent downstream
mediator of TGF-b1. Both proximal tubule cells (PTCs) and
cortical fibroblasts (CFs) are considered to be responsible for
the production of tubulointerstitial extracellular matrix (ECM).
These studies were undertaken to assess the profibrotic
effects of CTGF in an in vitro model of the human PTCs and
CFs, and to determine whether tranilast is effective in limiting
the in vitro matrix responses induced by CTGF. Primary
cultures of PTCs and CFs were exposed to CTGF (20 ng/
ml)7tranilast (100 lM). Cell hypertrophy and the secretion of
the ECM proteins fibronectin and collagen IV were
determined. The effects of tranilast on TGF-b1-induced CTGF
mRNA expression and on phosphorylation of Smad2 were
determined. CTGF significantly induced cell hypertrophy,
increased fibronectin, and collagen IV secretion in PTCs and
CFs. In all cases, the CTGF-induced increase in ECM protein
was inhibited in the presence of tranilast. Tranilast reduced
CTGF mRNA and phosphorylation of Smad2, which were
induced by TGF-b1 in PTCs and CFs. These results suggest
that tranilast is a potential effective antifibrotic compound
in the kidney, exerting its effects via inhibition of
TGF-b1-induced CTGF expression and downstream
activation of the Smad2 pathway in both PTCs and CFs.
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The tubulointerstitium of the kidney accounts for approxi-
mately 90% of the kidney volume. Injury to the tubulointer-
stitium, resulting in expanded extracellular matrix (ECM)
and tubular atrophy, is the key structural determinant of
progressive renal disease independent of the primary
pathology.1,2 Proximal tubule cells (PTCs) and cortical
fibroblasts (CFs) are the cellular elements primarily involved
in the pathological changes in human renal fibrosis.2,3
Transforming growth factor-b1 (TGF-b1) and more
recently connective tissue growth factor (CTGF) have been
recognized as important cytokines involved in renal fibrosis.
CTGF is considered to be a key downstream mediator of the
profibrotic effects of TGF-b1. It is clear that both PTCs and
CFs produce significant amount of TGF-b1 under basal
conditions,4,5 which is amplified in disease states and
correlates with clinical and histological markers of progres-
sive pathology.6 We have recently reported that CTGF
requires TGF-b1, signalling through the TbRII in PTCs and
CFs, to exert its fibrogenic response in this in vitro model.7
Tranilast (N-[3,4-dimethoxycinnamoyl]anthranilic acid)
is a drug initially used for its ‘antiallergy’ effects, where it is
thought to act as a mast cell-stabilizing agent.8 It has also
been used in disorders such as scleroderma, which are
associated with an excessive fibrotic response.9 In a small
pilot study in patients with advanced diabetic nephropathy,
tranilast was reported to slow the decline in glomerular
filtration rate over a 12-month period.10 More recently, we
have demonstrated in a rat model of experimental diabetes
mellitus that concurrent treatment with tranilast attenuates
both albuminuria and tubulointerstitial pathology. In this
study, we further demonstrated that tranilast blocked the
enhanced synthesis of collagen and non-collagen proteins
induced by TGF-b1 in CFs.11 CTGF is increasingly reported
as having a pathogenic role in diabetic complications,
including nephropathy. However, whether the pro-fibrotic
effects of CTGF can be modulated by tranilast in either PTCs
or CFs is unknown. Furthermore, the effects of tranilast on
TGF-b1-induced CTGF mRNA and TGF-b-induced Smad
signaling in both PTCs and CFs have not been studied.
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RESULTS
Cell cytotoxicity
Exposure of PTCs to 100 mM had no significant effect on the
levels of formazan release compared to control levels
(10672.0%; n¼ 4). Similarly, exposure to CFs to 100 mM
had no significant effect on the levels of formazan release
compared to controls (9370.9%, n¼ 4). These data indicate
that any effects of tranilast treatment in the current study
cannot be attributed to cytotoxicity.
Tranilast inhibits CTGF-induced cellular hypertrophy in PTCs
and CFs
Exposure of PTCs to CTGF caused a significant increase in
cell protein content per cell to 13376.7% (Po0.0001)
compared to control values (Figure 1a). Similarly in CFs,
exposure to CTGF induced a significant increase in cell
protein content per cell to 14178.7% (Po0.0001) of control
(Figure 1b). The hypertrophic effect of CTGF in both PTCs
and CFs was inhibited when the cells were incubated with
CTGF in the presence of tranilast.
Tranilast attenuates CTGF-induced matrix synthesis in PTCs
and CFs
The increase in cellular hypertrophy induced by CTGF in
PTCs and CFs was paralleled by an increase in the levels of
the markers of matrix deposition. Exposure of PTCs to
CTGF, respectively, increased fibronectin and collagen IV
secretion to 155722 and 4777124% (both Po0.005) of
control levels (Figure 2a and b). Similarly in CFs, exposure to
CTGF, respectively, increased fibronectin and collagen IV
secretion to 14878.9% (Po0.005) and 309767% (Po0.05)
of control levels (Figure 2c and d). The increased production
of fibronectin and collagen IV secretion by PTCs and CFs in
the presence of CTGF were inhibited in the presence of
tranilast.
Tranilast reduces TGF-b1-induced CTGF mRNA expression
We have previously demonstrated that TGF-b1 stimulated
CTGF with a peak induction at 24 h.7 Hence, experiments
were undertaken after exposure to the defined conditions for
24 h. PTCs and CFs exposed to 2 ng/ml TGF-b1 for 24 h
induced a respective 2.570.3 (Po0.005) and 2.570.2
(Po0.005) fold increase in CTGF mRNA expression
compared to control value. In both cell types, this induction
was inhibited by tranilast (Figure 3a and b).
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Figure 1 | Tranilast inhibits CTGF-induced cellular hypertrophy.
(a, black bars) PTCs and (b, open bars) CFs were exposed to control,
20 ng/ml CTGF, 20 ng/ml CTGF plus 100 mM tranilast, or 100 mM
tranilast alone for 48 h. Results are expressed as mean7s.e.m. and are
standardized as a percentage of the control values. ***Po0.0001 vs
control; ###Po0.0001 vs CTGF; n¼ 6.
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Figure 2 | Tranilast attenuates CTGF-induced matrix synthesis. (a,
black bars) PTCs and (b, open bars) CFs were exposed to control,
20 ng/ml CTGF, 20 ng/ml CTGF plus 100 mM tranilast, or 100 mM
tranilast alone for 48 h. (a and c) Fibronectin and (b and d) collagen IV
secretion were measured. Representative Western blots for fibro-
nectin, collagen, and Coomassie Brilliant Blue staining, which served
as a loading control, are shown. Results are mean7s.e.m. and are
standardized as a percentage of the control values. **Po0.005;
*Po0.05 vs control; ###Po0.0001; ##Po0.005, and #Po0.05 vs CTGF;
n¼ 6.
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Figure 3 | Tranilast inhibits TGF-b1-induced CTGF mRNA expres-
sion. (a, black bars) PTCs and (b, open bars) CFs were exposed to
control, 2 ng/ml TGF-b1, 2 ng/ml TGF-b1 plus 100 mM tranilast, or
100 mM tranilast alone for 24 h. CTGF mRNA expression was measured
by real-time PCR. Real-time PCR results were normalized to house-
keeping gene 18S and shown as fold change compared to control
value. **Po0.005 vs control and #Po0.05 vs TGF-b1; n¼ 6.
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Tranilast inhibits TGF-b-induced cellular hypertrophy and
matrix synthesis
We have recently demonstrated that tranilast blocked the
enhanced synthesis of collagen and non-collagen proteins
induced by TGF-b1 in CFs.11 To further confirm this
inhibitory effect on PTCs as well, PTC exposed to 2 ng/ml
TGF-b1 resulted in a significant increase in cell protein
content per cell to 17178.7% (Figure 4a) and 157710.0%
(Figure 4b) (both Po0.0001) compared to control values.
The hypertrophic effect of TGF-b1 was inhibited when the
cells were incubated with TGF-b1 in the presence of tranilast.
Tranilast alone had no effect on cellular protein content in
PTCs and CFs.
The cellular hypertrophy induced by TGF-b1 in PTCs and
CFs was paralleled by an increase in the levels of the markers
of matrix deposition. In PTCs, exposure to TGF-b1 increased
fibronectin and collagen IV secretion to 625792%
(Po0.0001) and 390790% (Po0.05), respectively, of
control levels (Figure 4c and d). The increases in fibronectin
and collagen secretion were inhibited in PTCs co-exposed to
TGF-b1 and tranilast. Exposure to tranilast alone had no
effect on these parameters. Similarly in CFs, exposure to
TGF-b1 increased fibronectin and collagen IV secretion to
15779.6% (Po0.005) and 510794% (Po0.0001), respec-
tively, of control levels. The increases in fibronectin and
collagen secretion were inhibited in CFs exposed to both
TGF-b1 and tranilast.
Tranilast inhibits TGF-b-induced phosphorylation of Smad2
We have previously demonstrated that TGF-b1 induced
pSmad2 with a peak induction at 30 min.7 Hence, these
experiments were performed after 30 min exposure to the
defined conditions. TGF-b1 induced pSmad2 in PTCs and
CFs within 30 min, which was inhibited by tranilast (Figure
5a and c). These data suggest that tranilast inhibits the
profibrotic effect of TGF-b1 via a reduction in pSmad
signaling.
We have also demonstrated that CTGF did not detectably
induce pSmad2 until 24 h.7 Hence, experiments were
performed at 24 h exposure to the defined conditions. These
demonstrated that tranilast inhibits CTGF-induced pSmad2
expression (Figure 5b and d), which may be explained by
upstream abrogation of the action of TGF-b1.Fib
ro
ne
ct
in
 s
ec
re
tio
n
(%
 co
ntr
ol)
Fi
br
on
ec
tin
 s
ec
re
tio
n
(%
 co
ntr
ol)
Fibronectin
Coomassie Coomassie
Co
lla
ge
n 
IV
 s
ec
re
tio
n
(%
 co
ntr
ol)
Co
lla
ge
n 
IV
 s
ec
re
tio
n
(%
 co
ntr
ol)
Collagen IV
Fibronectin
Coomassie Coomassie
Collagen IV
0
100
200
300
400
500
600
0
100
200
300
400
500
600
700
0
100
200
300
400
500
600
700
800
CF
CF
CF
PTCPTC
PTCa b
d
f
c
e
Co
ntr
ol
TG
F-
1
TG
F-
1+
Tra
n
Tra
n
Co
ntr
ol
TG
F-
1
TG
F-
1+
Tra
n
Tra
n
Co
ntr
ol
TG
F-
1
TG
F-
1+
Tra
n
Tra
n
Co
ntr
ol
TG
F-
1
TG
F-
1+
Tra
n
Tra
n
Co
ntr
ol
TG
F-
1
TG
F-
1+
Tra
n
Tra
n
Co
ntr
ol
TG
F-
1
TG
F-
1+
Tra
n
Tra
n
160
180
200
140
120
100
Ce
ll p
ro
te
in
 c
on
te
nt
 p
er
ce
ll 
(%
 co
ntr
ol)
80
60
40
20
0
160
180
140
120
100
80
60
40
20
0
160
180
140
120
100
Ce
ll p
ro
te
in
 c
on
te
nt
 p
er
ce
ll 
(%
 co
ntr
ol)
80
60
40
20
0
***
***
***
**
###
##
##
##
#
*
###
***
Figure 4 | Tranilast inhibits TGF-b1-induced cellular hypertrophy
and matrix synthesis in both PTCs and CFs. (Black bars) PTCs and
(open bars) CFs were exposed to control, 2 ng/ml TGF-b1, 2 ng/ml
TGF-b1 plus 100 mM tranilast, or 100 mM Tranilast alone for 48 h. (a and
b) Cell protein content normalized to cell number was used as a
marker of cell hypertrophy. (c and e) Fibronectin served as a marker
of non-collagenous protein and (d and f) collagen IV served as marker
of collagen synthesis. Representative Western blots for fibronectin,
collagen IV, and Coomassie Brilliant Blue staining, which served as a
loading control, are shown. Results are mean7s.e.m. and are
standardized as a percentage of the control values. ***Po0.0005 vs
control; ###Po0.0005 vs TGF-b1; n¼ 6.
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Figure 5 | Tranilast inhibits TGF-b-induced phosphorylation of
Smad-2. (a and c) PTCs and CFs were exposed to control, 2 ng/ml
TGF-b1, 2 ng/ml TGF-b1 plus 100mM tranilast, or 100 mM Tranilast alone
for 30 min. Similarly in CTGF, (b) PTCs and (d) CFs were exposed to
control, 20 ng/ml CTGF, 20 ng/ml CTGF plus 100 mM tranilast, or 100 mM
tranilast alone for 24 h.
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Data were assessed using a quantitative scoring method as
described in the Materials and Methods section and shown
for PTCs in Table 1A and for CFs in Table 1B.
DISCUSSION
The present study provides further information to suggest
that tranilast is an effective antifibrotic strategy in progressive
renal disease. We have demonstrated that tranilast prevents
CTGF-induced matrix production in human renal PTCs and
CFs, which is similar to the antifibrotic effect previously
observed in CFs treated with TGF-b1.11 In the present study,
we have additionally confirmed that tranilast effectively
blocks TGF-b1-induced matrix production in PTCs. Based
on our previous and current study findings, we hypothesize
that tranilast limits the antifibrotic effects of CTGF by
inhibiting TGF-b1 and downstream activation of pSmad2.
These in vitro findings suggest the basis for our recent
demonstration that tranilast ameliorates objective markers of
fibrosis in an animal model of diabetic nephropathy.11
Clearly, TGF-b1 and CTGF have been implicated in the
development of diabetic nephropathy.12–14 However, the
effect of tranilast on the manifestation of diabetic nephro-
pathy, that is, excessive tubulointerstitium matrix production
has not previously been demonstrated. Tranilast has pre-
viously been shown to block TGF-b1-induced fibrosis in the
skin.15,16 The current study supports its use as an antifibrotic
agent in circumstances where profibrotic cytokines other
than TGF-b1 are implicated.
The pharmacological effects of tranilast have not to date
been widely appreciated. Tranilast is an immunomodulatory
drug that inhibits the release of cytokines and chemical
mediators from various cells, including macrophages and
fibroblasts. Our data are supported by others who demon-
strated that tranilast suppresses hypertrophic scarring by
inhibiting collagen synthesis in fibroblasts, vascular smooth
muscle cells, and macrophages.10,15,17
Initial reports in small numbers of patients suggested that
tranilast slows the progression of advanced diabetic nephro-
pathy and treatment with tranilast may suppress the
accumulation of collagen in renal tissue. Hence, the
therapeutic value in advanced diabetic nephropathy has been
suggested.10 It has also been reported that tranilast suppresses
the elevation in mRNAs encoding the TGF-b type I and type
II receptor in balloon-injured arteries in a dose-dependent
manner.18 The mechanism has not been elucidated, but it has
been speculated that tranilast may act through the inhibition
of receptor tyrosine kinase and possibly receptor serine
threonine kinase activities.19
The blockade of the hypertrophic and pro-fibrotic effects
of CTGF by tranilast is consistent with the suggestion that
CTGF-induced renal fibrosis is mediated by facilitating the
action of TGF-b1. Several studies have shown that tranilast
inhibits TGF-b1 expression18,20,21 and TbR II-induced
phosphorylation of the type 1 receptor.18 Our findings that
tranilast inhibits TGF-b1-induced phosphorylation of Smad2
is consistent with these studies. Indeed, we have previously
demonstrated that tranilast inhibits TGF-b-induced matrix
production in vitro in human CFs.11 We cannot exclude the
possibility that tranilast may block integrins or other as yet
unidentified intracellular receptors that might serve as CTGF
receptors.22–25 However, the hypothesis that CTGF promotes
fibrosis through TGF-b1-dependent mechanisms is sup-
ported by a report from Abreu et al.22 and our recent work,7
which showed that CTGF may function as a chaperone to
modify the conformation or solubility of TGF-b1, and thus
facilitate TGF-b1 binding to the TbRII. The present study is
consistent with this view, as we have demonstrated that
tranilast inhibits TGF-b1-induced CTGF mRNA expression
Table 1 | Quantitation of pSmad2 in (A) PTCs and in (B) CFs
Treatment Positive staining cells (%) Score P-values
(A) Quantitation of pSmad2 in PTCs
Control-A 8.770.3 0
TGF-4b1 92.771.5 4+ 4Po0.0001 (vs control-A)
TGF-4b1+tranilast 10.072.6 1+ 4Po0.0001 (vs TGF-4b1)
Tranilast-A 8.070.6 0 4P40.05 (vs control-A)
Control-B 8.070.6 0
CTGF 85.370.3 4+ 4Po0.0001 (vs control-B)
CTGF+tranilast 7.071.5 0 4Po0.0001 (vs CTGF)
Tranilast-B 6.771.2 0 4P40.05 (vs control-B)
(B) Quantitation of pSmad2 in CFs
Control-C 4.070.6 0
TGF-4b1 94.771.5 4+ 4Po0.0001 (vs control-C)
TGF-4b1+tranilast 9.771.2 0 4Po0.0001 (vs TGF-4b1)
Tranilast-C 3.370.9 0 4P40.05 (vs control-C)
Control-D 5.370.9 0
CTGF 78.071.5 4+ 4Po0.0001 (vs control-D)
CTGF+tranilast 4.770.9 0 4Po0.0001 (vs CTGF)
Tranilast-D 6.071.2 0 4P40.05 (vs control-D)
CF=cortical fibroblast; CTGF=connective tissue growth factor; PTC=proximal tubule cell; TGF-b1=transforming growth factor-b1; tranilast=N-[3,4-dimeth-xycinnamoyl]an-
thranilic acid.
N.B.: Score calculation: o10% positive cells=0, 10–25%=1+, 25–50%=2+, 50–75%=3+, and 75–100%=4+.
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and TGF-b1-induced pSmad2. Hence, the molecular me-
chanisms of tranilast as an antifibrotic agent on TGF-b1 and
CTGF have been further explored.
In smmary, tranilast limits the observed increase in matrix
protein produced by PTCs and CFs in response to the
profibrotic cytokines TGF-b1 and CTGF, which are clearly
implicated in progressive renal disease. It has no observable
toxic effects with respect to cell viability at its effective
concentration in vitro. Many pharmacological agents pro-
posed to limit collagen deposition in fibrotic diseases are
clinically unacceptable because of toxicity, or efficacy.
Tranilast appears to be free from these limitations and it is
proven to have minimum long-term side effects.16 These
studies should form the basis for future studies as to its
usefulness in the treatment of human disease associated with
kidney fibrosis. Moreover, this is the first study, to our
knowledge, to explore the molecular mechanisms of tranilast
on TGF-b signalling and on TGF-b1-induced CTGF expres-
sion.
MATERIALS AND METHODS
Cell culture
Segments of macroscopically and histologically normal renal
cortex were obtained under aseptic conditions from patients
undergoing nephrectomy for small (o6 cm) tumors. Patients
were accepted for inclusion into the study if there was no history
of renal or systemic disease known to be associated with
tubulointerstitial pathology, which was confirmed by subsequent
histopathology. Written informed consent was obtained from each
patient before surgery and ethics approval for the study was
obtained from the Royal North Shore Hospital Human Research
Ethics Committee.
The methods for primary culture of both PTC and CF are
described in detail elsewhere.4,26 In brief, the kidney cortex was
dissected from the medulla, finely minced, and then digested by
collagenase (383 U/mg from Worthington, NJ, USA) for 30 min at
371C and passed through a 100mm mesh. The filtrate was
resuspended in 50 ml of 45% Percoll (Pharmacia, Uppsala, Sweden)
and centrifuged at 20 000 r.p.m. at 401C for 30 min. The lowermost
tissue band containing highly purified PTCs and the top band
containing CFs were carefully removed and washed. The PTC
fragment pellet was resuspended in serum-free hormonally defined
media consisting of 1:1 (vol:vol) Dulbecco’s modified Eagle’s media
and Hams F-12 (Trace, Australia), supplemented with 10 ng/ml
(1.64 nM) epidermal growth factor, 5 mg/ml human transferrin,
5 mg/ml (0.87 mM) bovine insulin, 0.05 mM hydrocortisone, 50 mM
prostaglandin E1, 50 nM selenium, and 5 pM tri-iodothyronine (all
from Sigma, USA). The CF pellet was resuspended in Dulbecco’s
modified Eagle’s media and Hams F-12 containing 10% fetal calf
serum (Invitrogen, Australia). Passage 2 cells were used for all
experiments. The ultrastructure, growth, and immunohistochem-
istry of both PTC and CF have been well characterized in our
laboratory and shown to reproducibly reflect the biology and
physiology of their in vivo counterparts.4,26
Antibodies and recombinant proteins
TGF-b1 was purchased from Sigma (MO, USA) and recombinant
human CTGF was a generous gift from FibroGen (CA, USA). Mouse
monoclonal fibronectin antibody was from Neomarkers (CA, USA)
and rabbit polyclonal collagen IV antibody was from Abcam
(Cambridge, UK). Phospho-Smad2 antibody was purchased from
Chemicon, USA.
Experimental protocol
Cells were grown to approximately 80% confluence and then
quiesced by incubation for 24 h in basic media (Dulbecco’s modified
Eagle’s media and Hams F-12 containing 5 ng/ml human transfer-
rin). Subsequently, the cells were exposed to the various experi-
mental conditions described below for a further 48 h, unless
otherwise described. Both PTC and CFs were exposed to medium
containing 5 mM glucose plus 0.01% bovine serum albumin under
experimental conditions as defined below. The concentrations used
in these experimental conditions were determined by initial
dose–response curve in both PTCs and CFs using between 2 and
200 ng/ml of CTGF. This determined that 20 ng/ml achieved
maximal expression of fibronectin with no cellular toxicity. The
effective concentration of tranilast was determined by a dose–r-
esponse curve using 30, 100, and 300mM tranilast. The 100 mM dose
was chosen as it had potent inhibitory effect on TGF-b1- and CTGF-
induced matrix production, but no toxic effect was observed on the
cells. This dose had been previously used in other models.27,28
Initial experiments performed in PTC assessed the effect of
CTGF7tranilast or tranilast alone in both PTCs and CFs on cellular
protein content as a marker of cellular hypertrophy, and on
fibronectin and collagen type IV secretion as markers of ECM
production. Collagen type IV was chosen as marker of synthesis of
collagen-based protein. Fibronectin was chosen as a non-collage-
nous protein that serves as a scaffold for the deposition of other
proteins. Furthermore, it functions as a fibroblast chemoattractant
and promotes their differentiation, which may be a crucial
phenomenon in the pathogenesis of tubulointerstitial fibrosis.24
Subsequent experiments assessed the effects of tranilast in both
PTC and CFs on TGF-b-induced CTGF mRNA expression, TGF-b,
and CTGF-induced Smad signaling.
Measurement of cytotoxicity
Cell viability following exposure of 100 mM tranilast was assessed
using the CellTiter 96 AQueous One Solution kit (Promega,
USA). The absorbance of the formazan released in each sample
read and the results standardized to control. The levels of formazan
in the culture supernatant reflect mitochondrial activity, thus a
reduction in formazan levels released by cells represents a cytotoxic
effect.
Cellular hypertrophy
Cellular hypertrophy is reflected by an increase in protein per cell as
described previously by our group and others.29–31 Manual cell
counts were performed on trypsinized cells using a hemocytometer.
Cellular protein was quantitated using BioRad protein assay
(Hercules, CA, USA). Total cellular protein content normalized for
cell number was determined as a marker of cellular hypertrophy.
Fibronectin and collagen IV Western blotting
Fibronectin and collagen IV secretion were determined by Western
blotting on cell culture supernatants. Samples were subjected to
sodium dodecylsulfate-polyacrylamide gel electrophoresis under
reducing conditions. Proteins were then transferred to Hybond ECL
nitrocellulose membrane (Amersham Pharmacia Biotech, UK).
Nonspecific binding sites were blocked for 1 h (5% non-fat milk
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and 0.1% Tween-20 in phosphate-buffered saline (PBS)), after
which the membranes were incubated in primary fibronectin and
collagen IV antibodies overnight at 41C, followed by washing four
times after which they were incubated with peroxidase-labelled
secondary antibodies (Amersham Pharmacia Biotech, UK) for 1 h
and again washed four times. The blots were then detected using
ECL (Amersham Pharmacia Biotech, UK). The bands corresponding
to fibronectin (220 kDa) and collagen IV (180 kDa) were quantitated
using NIH Image software v1.60. Coomassie Brilliant Blue staining
was used to confirm that an equal amount of protein was loaded in
each lane.
Immunocytochemistry staining
PTCs and CFs were treated with TGF-b1 or CTGF7tranilast or
tranilast alone for 48 h as described in the Materials and Methods
sections and fixed on coverslips using ice-cold 4% formalin for
30 min followed by three times washing in PBS. Cells were then
permeabilized with 0.2% Triton X-100 for 20 min followed by three
washing in PBS. Cells were treated with 4% hydrogen perioxide in
PBS to quench the endogenous peroxidase activity and then the
nonspecific background was blocked using serum-free protein block
(Dako, USA). Cells were incubated with pSmad2 primary antibody
(1:200) at room temperature for 1 h followed by three washing in
PBS. LSAB2 system-HRP was used for detection of pSmad2
according the manufacturer’s instructions (Dako, USA). Mayer’s
hematoxylin was used to counterstain the cells. A negative control
(non-pSmad2 antibody) was performed. Coverslips were mounted
on glass slides using Dako glycerol mounting media. Slides were
blinded and three random fields were digitized using a Nikon
microscope attached to a digital camera. Data was quantitated using
quantitative scoring method as described by McDonald and
Pilgram.32 In total, 100 cells were randomly chosen and counted
on each slide. Less than 10% positive staining cells was scored 0,
10–25% positive cells was scored 1þ , 25–50% positive cells was
scored 2þ , 50–75% positive cells was score 3þ , and 75–100%
positive cells was scored 4þ .
Real-time reverse transcription polymerase chain reaction
Real-time polymerase chain reaction (PCR) following reverse
transcription was used to assess transcript levels of CTGF. To ensure
equal loading of cDNA samples, concurrent PCR reactions for 18S
was performed. Both water blank and non-reverse-transcribed RNA
samples were used as negative controls. Briefly, total RNA was
extracted using RNeasy Mini kit (Qiagen, Australia) according to the
manufacturer’s instructions. Total RNA (2 mg) was treated with
DNase I (Invitrogen, USA) and then cDNA was synthesized using
reverse transcriptase Superscript II RT (Invitrogen, USA). Specific
primers for the use of SYBR Green were designed as follows: CTGF –
forward, 50-GGCTTACCGACTGGAAGAC-30 and reverse, 50-AG-
GAGGCGTTGTCATTGG-30. 18S served as an internal control:
forward, 50-CGGCTACCACATCCAAGGAA-30 and reverse, 50-
GCTGGAATTACCGCGGCT-30. Primers specificity in real-time
PCR reactions was confirmed using reverse transcription PCR. A
25 ml of real-time PCR reaction included Brilliant SYBR Green QRT-
PCR Master Mix according to the manufacturer’s instructions
(Stratagene, USA). Real-time quantitations were performed on the
Bio-Rad iCycler iQ system (CA, USA). The fluorescence threshold
value was calculated using the iCycle iQ system software. The
calculation of relative change in mRNA was performed using the
delta–delta method,33 with normalization for the housekeeping
gene 18S.
Statistical analysis
All results are expressed as a percentage of the control values
(100%), with the exception of real-time PCR results, which are
expressed as a fold change compared to the control value.
Experiments were in duplicates and performed in at least three
different culture preparations, hence n¼ 6. Results are expressed as
mean7s.e.m. Statistical comparisons between groups were made by
analysis of variance, with pairwise multiple comparisons made by
Fisher’s protected least-significant difference test. Analyses were
performed using the software package, Statview version 4.5 (Abacus
Concepts Inc., Berkley, CA, USA). P-values less than 0.05 were
considered significant.
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